AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9414376 — intervention group
Group type: COMPARATOR
Intervention: Seated on a chair designed to alleviate workload
Number of subjects: 10
Study 9414376 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling posture
Number of subjects: 10
Study 8099640 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil
Number of subjects: 123
Study 8099640 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil and fish oil
Number of subjects: 123
Study 8099640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 3429863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg twice daily for 3 weeks
Number of subjects: 40
Study 3429863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27927030 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance specific rehabilitation, 20 treatment sessions
Number of subjects: 119
Study 27927030 — intervention group
Group type: COMPARATOR
Intervention: Control group treatments to reduce limitations at activity and body function level, 20 treatment sessions
Number of subjects: 119
Study 27927030 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up for fallers
Number of subjects: 119
Study 27927030 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up for responders at BBS
Number of subjects: 119
Study 25873634 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 50 mg QW + MTX
Number of subjects: 91
Study 25873634 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 25 mg QW + MTX
Number of subjects: 91
Study 25873634 — intervention group
Group type: COMPARATOR
Intervention: Placebo QW + MTX
Number of subjects: 91
Study 26058036 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ng/kg body weight LPS
Number of subjects: 40
Study 26058036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22752489 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks)
Number of subjects: 20
Study 22752489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 38
Study 21094804 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab
Number of subjects: 38
Study 21094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 38
Study 18236373 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 19
Study 18236373 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 19
Study 16837434 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglyceride (ST)
Number of subjects: 236
Study 14617717 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice combined with active neuromuscular stimulation
Number of subjects: 34
Study 14617717 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice along with active stimulation
Number of subjects: 34
Study 14617717 — intervention group
Group type: COMPARATOR
Intervention: No active stimulation assistance (control group)
Number of subjects: 34
Study 10651692 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen bath-PUVA
Number of subjects: 12
Study 10651692 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band UVB phototherapy
Number of subjects: 12
Study 8673350 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment (alprazolam + sulpiride)
Number of subjects: 72
Study 8673350 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment (alprazolam + sulpiride) plus social support by volunteers (SSV)
Number of subjects: 72
Study 8673350 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment (alprazolam + sulpiride) plus structured psychotherapy (autogenous training)
Number of subjects: 72
Study 8673350 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated strategy combining psychopharmacology and psychosocial interventions (SSV with or without structured psychotherapy)
Number of subjects: 72
Study 1733156 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 26
Study 1733156 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 26
Study 6376144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (3 X 2 inhalations)
Number of subjects: 16
Study 6376144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 X 2 inhalations)
Number of subjects: 16
Study 31854843 — intervention group
Group type: COMPARATOR
Intervention: Warming (WA)
Number of subjects: 0
Study 31854843 — intervention group
Group type: COMPARATOR
Intervention: Control (CK)
Number of subjects: 0
Study 31854843 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming and Straw Application (WS)
Number of subjects: 0
Study 31854843 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean plots
Number of subjects: 0
Study 31854843 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter wheat plots
Number of subjects: 0
Study 31854843 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean growing season
Number of subjects: 0
Study 31854843 — intervention group
Group type: EXPERIMENTAL
Intervention: α diversity indices
Number of subjects: 0
Study 28847527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) administered simultaneously with modulated electrohyperthermia (mEHT)
Number of subjects: 15
Study 28847527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) administered after modulated electrohyperthermia (mEHT)
Number of subjects: 15
Study 28847527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) administered before modulated electrohyperthermia (mEHT)
Number of subjects: 15
Study 28847527 — intervention group
Group type: EXPERIMENTAL
Intervention: Solely intravenous ascorbic acid (IVAA)
Number of subjects: 15
Study 26363163 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training (TR group) - twice daily exposure to 4 odours (rose, eucalyptus, lemon, clove) for approximately 12 weeks
Number of subjects: 0
Study 26363163 — intervention group
Group type: COMPARATOR
Intervention: No olfactory training (noTR group)
Number of subjects: 0
Study 23394837 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy (WEC)
Number of subjects: 110
Study 23394837 — intervention group
Group type: COMPARATOR
Intervention: Conventional air colonoscopy (AC)
Number of subjects: 110
Study 21176784 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg modafinil + placebo
Number of subjects: 12
Study 21176784 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg THC + placebo
Number of subjects: 12
Study 21176784 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg modafinil + 15 mg THC
Number of subjects: 12
Study 21176784 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 12
Study 19237404 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled non-heart beating donation (CNHBD) kidneys
Number of subjects: 79
Study 19237404 — intervention group
Group type: COMPARATOR
Intervention: Heart beating donation (HBD) kidneys
Number of subjects: 79
Study 19237404 — intervention group
Group type: EXPERIMENTAL
Intervention: CNHBD kidneys
Number of subjects: 79
Study 19237404 — intervention group
Group type: COMPARATOR
Intervention: HBD kidneys
Number of subjects: 79
Study 17966746 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 54
Study 17966746 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 54
Study 17966746 — intervention group
Group type: COMPARATOR
Intervention: Non-concordance cases
Number of subjects: 54
Study 15545308 — intervention group
Group type: EXPERIMENTAL
Intervention: M100240 50 mg with a high-fat meal
Number of subjects: 30
Study 15545308 — intervention group
Group type: COMPARATOR
Intervention: M100240 50 mg under fasted conditions
Number of subjects: 30
Study 12399343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing intervention (active treatment with care management by practice nurses over 24 months)
Number of subjects: 211
Study 12399343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing intervention
Number of subjects: 211
Study 9806290 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 0
Study 9806290 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 7796302 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery mediation instructions
Number of subjects: 24
Study 7796302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizarre imagery instructions
Number of subjects: 24
Study 7796302 — intervention group
Group type: EXPERIMENTAL
Intervention: Image mediator for every face-name pair
Number of subjects: 24
Study 7796302 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of original mediator during 1-week recall
Number of subjects: 24
Study 7796302 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to form image mediators
Number of subjects: 24
Study 7796302 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased focus during encoding
Number of subjects: 24
Study 1972648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg twice a day for 4 days)
Number of subjects: 11
Study 1972648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 514499 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque 280 mg I/ml
Number of subjects: 21
Study 514499 — intervention group
Group type: COMPARATOR
Intervention: Conray meglumine 282 mg I/ml
Number of subjects: 21
Study 6414060 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (E2)
Number of subjects: 0
Study 6414060 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P)
Number of subjects: 0
Study 6414060 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + P
Number of subjects: 0
Study 6414060 — intervention group
Group type: COMPARATOR
Intervention: Untreated ovariectomized women
Number of subjects: 0
Study 6414060 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruating women in follicular phase
Number of subjects: 0
Study 6414060 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups studied (including untreated)
Number of subjects: 0
Study 30869798 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 30869798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study 29941708 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi‐Zhi‐Wei‐Tong granules
Number of subjects: 197
Study 26809275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum 25(OH)D (Q5)
Number of subjects: 1000
Study 24641604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subcision and cryoroller
Number of subjects: 30
Study 24641604 — intervention group
Group type: COMPARATOR
Intervention: Combined subcision and dermaroller
Number of subjects: 30
Study 22037718 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty with measured bleeding
Number of subjects: 71
Study 20200548 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-guided slow-breathing (DGB) exercise
Number of subjects: 40
Study 20200548 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 40
Study 19065434 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacle use
Number of subjects: 0
Study 19065434 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires and focus group discussions
Number of subjects: 0
Study 19065434 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to spectacle use
Number of subjects: 0
Study 19065434 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing practices of local opticians
Number of subjects: 0
Study 15561050 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed perfusion system with heparin coating and centrifugal pump
Number of subjects: 41
Study 15561050 — intervention group
Group type: COMPARATOR
Intervention: Conventional system with uncoated circuit, roller pump, and hard-shell venous reservoir
Number of subjects: 41
Study 11376665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin in the form of transdermal therapeutic system releasing 5 mg of nitroglycerin in 24 h
Number of subjects: 30
Study 9259112 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid (ASA) per day
Number of subjects: 466
Study 9259112 — intervention group
Group type: COMPARATOR
Intervention: nicametate citrate (a vasodilator)
Number of subjects: 466
Study 8029782 — intervention group
Group type: EXPERIMENTAL
Intervention: Loderix (setastinum)
Number of subjects: 21
Study 8029782 — intervention group
Group type: COMPARATOR
Intervention: Hismanal (astemizole)
Number of subjects: 21
Study 3125269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg diflunisal 2 h preoperatively and then 500 mg twice daily for 2.5 days
Number of subjects: 169
Study 3125269 — intervention group
Group type: COMPARATOR
Intervention: Veralgin (1 tablet twice daily beginning 2 h prior to operation)
Number of subjects: 169
Study 28844518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus one-sixth molar sodium bicarbonate
Number of subjects: 93
Study 28844518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydration)
Number of subjects: 93
Study 27184779 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 INH (20,000 units every other day for 2 weeks)
Number of subjects: 18
Study 27184779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered every other day for 2 weeks)
Number of subjects: 18
Study 27184779 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 INH (measured before and after plasmapheresis)
Number of subjects: 18
Study 27184779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (measured before and after plasmapheresis)
Number of subjects: 18
Study 24412649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine precursor depletion (tyrosine and phenylalanine deficient drink)
Number of subjects: 13
Study 24412649 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid mixture (control)
Number of subjects: 13
Study 22851734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g/d for 3 days)
Number of subjects: 12
Study 22851734 — intervention group
Group type: COMPARATOR
Intervention: White chocolate (flavanol-free)
Number of subjects: 12
Study 19034538 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous ozone (HealOzone) applied for 30 seconds
Number of subjects: 40
Study 19034538 — intervention group
Group type: COMPARATOR
Intervention: 1% chlorhexidine gel (Corsodyl) applied for 30 seconds
Number of subjects: 40
Study 17687578 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive visuo-motor therapy system (VR-based motor neurorehabilitation)
Number of subjects: 0
Study 15792199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vektor-Titan stem in cementless THR
Number of subjects: 250
Study 11680727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-caval venous cannulation and crystalloid cardioplegia (Group A)
Number of subjects: 60
Study 11680727 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial cannulation and crystalloid cardioplegia (Group B)
Number of subjects: 60
Study 11680727 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial cannulation and blood cardioplegia (Group C)
Number of subjects: 60
Study 9643619 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 9643619 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 9643619 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 8044962 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg/d SC for 1 month)
Number of subjects: 458
Study 8044962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 2854455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg per day orally for 14 days
Number of subjects: 38
Study 2854455 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38
Study 30471928 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) 800 kcal for 4 weeks
Number of subjects: 20
Study 30471928 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 20
Study 28737409 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg immediate-release tablet of ibuprofen
Number of subjects: 37
Study 26138726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 60
Study 26138726 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 60
Study 26138726 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 23897066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise advice)
Number of subjects: 450
Study 20626531 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pulse regimen (200 mg b.i.d. for 1 week, off for 3 weeks)
Number of subjects: 50
Study 20626531 — intervention group
Group type: COMPARATOR
Intervention: Continuous regimen (Itraconazole 100 mg b.i.d. continuously)
Number of subjects: 50
Study 19414509 — intervention group
Group type: EXPERIMENTAL
Intervention: InVEST training
Number of subjects: 138
Study 19414509 — intervention group
Group type: COMPARATOR
Intervention: NIA strength training program
Number of subjects: 138
Study 19414509 — intervention group
Group type: EXPERIMENTAL
Intervention: InVEST training (post hoc analysis)
Number of subjects: 138
Study 17710021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose I-131 therapy
Number of subjects: 50
Study 17710021 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed)
Number of subjects: 50
Study 15511470 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake group (thoracic epidural anesthesia at T4-T5)
Number of subjects: 60
Study 15511470 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anesthesia with double-lumen intubation and thoracic epidural anesthesia)
Number of subjects: 60
Study 11778950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B1 (75 mg, once a day) for 1 month
Number of subjects: 50
Study 11778950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg, twice a day) for 1 month
Number of subjects: 50
Study 11778950 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 9472838 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day
Number of subjects: 384
Study 9472838 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg/day
Number of subjects: 384
Study 9472838 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 200 mg/day
Number of subjects: 384
Study 9472838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 8564350 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive breast forms
Number of subjects: 67
Study 2565119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 10
Study 2565119 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 10
Study 2565119 — intervention group
Group type: COMPARATOR
Intervention: Control (Drug-free period)
Number of subjects: 10
Study 1104060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 500
Study 1104060 — intervention group
Group type: COMPARATOR
Intervention: No heparin prophylaxis (Control)
Number of subjects: 500
Study 31679670 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh tourniquet for 60 minutes followed by calf tourniquet inflation and thigh tourniquet deflation
Number of subjects: 20
Study 31679670 — intervention group
Group type: COMPARATOR
Intervention: Thigh tourniquet throughout surgery
Number of subjects: 20
Study 28213005 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 125
Study 28213005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 25733201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg per day) plus Metformin (1000 mg twice per day)
Number of subjects: 25
Study 25733201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25733201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus Metformin
Number of subjects: 25
Study 23392759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg two or three times a day
Number of subjects: 0
Study 23392759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21365504 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve preservation
Number of subjects: 32
Study 21365504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 20306771 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health complaints and use of medicines among females
Number of subjects: 514
Study 20306771 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of information from package insert
Number of subjects: 514
Study 20306771 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of information from parents or adult relatives
Number of subjects: 514
Study 20306771 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of information from friends or schoolmates
Number of subjects: 514
Study 16904773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sedation (Fentanyl and Midazolam)
Number of subjects: 611
Study 16904773 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (1% lignocaine)
Number of subjects: 611
Study 16904773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined local anesthesia and sedation
Number of subjects: 611
Study 16904773 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither sedation nor local anesthesia
Number of subjects: 611
Study 16904773 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia only
Number of subjects: 611
Study 16904773 — intervention group
Group type: COMPARATOR
Intervention: Sedation only
Number of subjects: 611
Study 16904773 — intervention group
Group type: COMPARATOR
Intervention: Combined local and sedation
Number of subjects: 611